Skip to Content

Regeneron Pharmaceuticals Inc REGN Stock Quote

| Rating as of


After hours: 824.84 0.00 | 0.00 %

| Currency in USD

  • Last Close 823.38
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Blend
  • Day Range 818.30  –  831.50
  • Year Range 668.00  –  847.50
  • Market Cap 89.5436 Bil
  • Volume / Avg 464,502.0 /  590,684.9
  • Price / Sales 7.39
  • Price / Book 3.73
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis REGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Regeneron's Solid Immunology Drug Dupixent and Growing Oncology Pipeline Support a Narrow Moat

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat. Lead drug Eylea has global sales around $9 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned, as its high-dose formulation should allow it to continue to hold strong market share against biosimilars and Roche's new branded drug, Vabysmo.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics REGN

Company Profile REGN

Business Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

777 Old Saw Mill River Road
Tarrytown, NY, 10591-6707
Industry Biotechnology
Employees 11,851

Related Articles REGN

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of REGN’s competitive advantage.

Regeneron Pharmaceuticals Inc


Amgen Inc


Novartis AG Registered Shares


Roche Holding AG

+$1.46 (0.18%) −$1.71 (0.63%) −$0.77 (0.83%) −$1.65 (0.66%)
Market Cap
89.54 Bil143.19 Bil190.16 Bil199.18 Bil
Biotechnology Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Regeneron Pharmaceuticals Inc Stock

No. REGN does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

REGN’s market cap is 89.54 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

REGN’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

REGN’s price/sales is 7.39.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

REGN’s price/forward earnings is 21.77.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

REGN’s price/book is 3.73.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See REGN’s valuation ratios compared to the Market Index.

REGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare REGN’s historical performance against its industry peers and the overall market.